Clinical Scorecard: Exploring the Significance of Hope: A Hermeneutic Phenomenological Investigation into the Experiences of Patients with Adrenocortical Carcinoma
At a Glance
Category
Detail
Condition
Adrenocortical Carcinoma (ACC)
Key Mechanisms
Aggressive malignancy of the adrenal glands with high recurrence rates and poor survival outcomes.
Target Population
Patients diagnosed with Adrenocortical Carcinoma.
Care Setting
Oncology and Endocrinology clinical settings.
Key Highlights
ACC is characterized by significant psychological burden and uncertainty.
Living with ACC involves navigating life-prolonging treatments and existential challenges.
Participants expressed a strong need for hope and compassionate care.
Surgical resection is the cornerstone of management for ACC.
Adjuvant mitotane therapy is recommended for patients at moderate to high risk of recurrence.
Guideline-Based Recommendations
Diagnosis
ACC is often misdiagnosed, leading to treatment delays.
Management
Surgical resection is preferred for complete oncological resection.
Adjuvant mitotane therapy is recommended for 2 to 5 years.
Monitoring & Follow-up
Maintain plasma mitotane levels between 14-20mg/L.
Risks
Adverse effects of treatment include endocrine, gastrointestinal, hepatic, haematological, and neurological complications.
Patient & Prescribing Data
Individuals diagnosed with ACC, including those with advanced disease.
Combination chemotherapy (EDP) is recommended for advanced or progressive disease.
Clinical Best Practices
Incorporate psychological support into treatment plans for ACC patients.
Utilize a person-centered approach to care that addresses the emotional and social impacts of ACC.
